Pages
- Adcirca®
- Adcirca® FAQ
- Aironite®
- Ambrisentan
- BiPAP / CPAP
- Bosentan
- Calcium Channel Blockers
- Coumadin®
- Digitalis
- Diuretics
- Endothelin Receptor Antagonists
- Epoprostenol for Injection
- Epoprostenol sodium
- Flolan®
- Iloprost
- Inhaled Treprostinil
- INOmax®
- Jantoven®
- Letairis®
- Marfarin®
- Nitric Oxide
- Nitrite
- Other Drugs and Treatments
- Oxygen
- Phosphodiesterase type-5 Inhibitor
- Prostacyclin
- PTE
- Remodulin®
- Revatio®
- Sildenafil Citrate
- Sitaxsentan Sodium
- Tadalafil
- Thelin®
- Tracleer®
- Tracleer® FAQ
- Transplant
- Treprostinil
- Tyvaso®
- Under FDA Review
- Veletri®
- Ventavis®
- Viagra®
- Volibris®
- Warfarin
Phosphodiesterase type-5 Inhibitor
A phosphodiesterase type-5 inhibitor, often shortened to PDE-5 inhibitor, is a drug used to block the degradative action of phosphodiesterase type-5 on cyclic GMP in the smooth muscle cells lining the blood vessels supplying the corpus cavernosum of the penis. These drugs are used in the treatment of erectile dysfunction and were the first effective oral treatment available for the condition. Because PDE-5 is also present in the arterial wall smooth muscle within the lungs, PDE-5 inhibitors have also been found to be effective for the treatment of pulmonary hypertension, a disease in which blood vessels in the lungs become abnormally narrow.
Two drugs in this class have been approved for the treatment of Pulmonary Hypertension:
Page Reviewed/Edited: November 2010
In The News
- January 14, 2012
- Cardiac Uses of Phosphodiesterase-5 Inhibitors
- December 16, 2011
Beyond the Abstract - Are phosphodiesterase type 5 Inhibitors associated with vision-threatening adverse events?- September 13, 2011
- Novel phosphodiesterase type 5 modulators: a patent survey (2008 - 2010).
- April 23, 2011
- Vardenafil Eases Symptoms of Pulmonary Arterial Hypertension
- December 14, 2010
- Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease

.jpg)